We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Predicts Mortality Risk for Peripheral Artery Disease Patients

By LabMedica International staff writers
Posted on 04 Nov 2016
Print article
Image: The LCMS‐8050 CL triple quadrupole mass spectrometer (Photo courtesy of Shimadzu).
Image: The LCMS‐8050 CL triple quadrupole mass spectrometer (Photo courtesy of Shimadzu).
Production of the proatherogenic metabolite, trimethylamine N‐oxide (TMAO), from dietary nutrients by intestinal microbiota enhances atherosclerosis and is associated with atherosclerotic coronary artery disease in humans.

Peripheral artery disease (PAD) is a common manifestation of systemic atherosclerosis and is associated with significantly increased cardiovascular death and mortality and it affects over 27 million people across Europe and North America.

Scientists associated with the Cleveland Clinic (Cleveland, OH, USA) carried out a single‐center prospective cohort study and enrolled 821 sequential consenting patients who underwent elective, non-urgent coronary angiographic evaluation at the Cleveland Clinic between 2001 and 2007. A confirmed diagnosis of PAD was based primarily on the type of PAD, based on reporting evidence of stenosis at the corresponding vasculature. Participants were followed for five years between 2001 and 2007.

The team collected fasting blood samples using EDTA tubes at the time of cardiac catheterization, immediately prior to heparin injection. Creatinine clearance was estimated using the Cockcroft‐Gault equation. Myeloperoxidase was determined by the CardioMPO assay (Cleveland Heart Labs, Cleveland, OH, USA). TMAO, choline, and betaine levels in plasma were determined using stable isotope dilution high‐performance liquid chromatography with online electrospray ionization tandem mass spectrometry on Shimadzu LCMS‐8050 CL Triple Quadrupole mass spectrometer using d9‐(trimethyl)‐labeled internal standards.

In the study cohort, the median TMAO level was 4.8 μmol/L (interquartile range 2.9–8.0 μmol/L), which was similar between patients with extracranial carotid artery stenosis (CAS) and non‐CAS. Subjects with elevated plasma TMAO levels were more likely to be older, with diabetes, with elevated high‐sensitivity C‐reactive protein (hsCRP), as well as with lower estimated glomerular filtration rate (eGFR). In contrast, prior history of CAD, smoking status, myeloperoxidase levels, apolipoprotein B levels, and medication use, were similar across TMAO levels. The incidence of both short- and long-term death progressively increased as blood levels of TMAO rose among patients with PAD. Compared to patients with the lowest levels, those with the highest levels of TMAO were 2.7 times more likely to die of any cause during the course of the five-year study.

W. H. Wilson Tang, MD, the lead author of the study said, “TMAO testing is available for clinical use, and these findings point to the potential for TMAO to help improve selection of high-risk PAD patients. Since people who are vegetarian or vegan or who follow the Mediterranean diet has been reported to have lower TMAO levels, more aggressive dietary counseling in patients with high TMAO levels is warranted.” The study was published on October 19, 2016, in the Journal of the American Heart Association.

Related Links:
Cleveland Clinic
Cleveland Heart Labs
Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.